Share this story with a colleague

FDA user fee reauthorization faces obstacles

Differences between House and Senate versions of bills reauthorizing the FDA Prescription Drug User Fee Act could delay the bill's progress. Differences include terms for exclusivity periods for new antibiotics, the FDA's mission and guidelines for how the agency determines devices' risks.